ReviewCancers2019
Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.EJNMMI physics · 2026Review
- Enhanced tumor retention and therapeutic potency in radionuclide therapy using GSH-induced self-assembling peptides.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Article
- Comparison of the dosimetry and cell survival effect ofEJNMMI physics · 2024Article
- Synthesis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Synthesis and Biologic Evaluation of an Iodine-Labeled Entecavir Derivative for Anti-hepatitis B Virus Activity.Nuclear medicine and molecular imaging · 2024Article
- A review of metallic nanoparticles: present issues and prospects focused on the preparation methods, characterization techniques, and their theranostic applications.Frontiers in chemistry · 2024Review
- Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?EJNMMI radiopharmacy and chemistry · 2023Review
- Improved radiosynthesis ofInternational journal of radiation biology · 2023Article
- Experimental validation of Monte Carlo dosimetry for therapeutic beta emitters with radiochromic film in a 3D-printed phantom.Medical physics · 2023Article
- Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review.Current issues in molecular biology · 2022Review
- Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.Molecular cancer therapeutics · 2022Article
- Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy.Biomolecules · 2022Review
- Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors.Endocrine-related cancer · 2022Article
- Compensating Positron Range Effects of Ga-68 in Preclinical PET Imaging by Using Convolutional Neural Network: A Monte Carlo Simulation Study.Diagnostics (Basel, Switzerland) · 2021Article
- An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- Targeted Brain Tumor Radiotherapy Using an Auger Emitter.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research.Pharmaceutics · 2019Review
- Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Compared to external beam radiotherapy, targeted radionuclide therapy (TRT) allows for systemic radiation treatment of metastatic lesions. Published work on recent strategies to improve patient management and response to TRT through individualising patient treatment, modifying treatment pharmacokinetics and increasing anticancer potency are discussed in this review, with a special focus on the application of clinically evaluated radiolabelled ligands and peptides in the treatment of neuroendocrine and prostate cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.